重新评估当代生育治疗实践独立相关的不良产科结局:一项美国前瞻性队列研究
该前瞻性队列在美国单一生育中心纳入656例单胎活产,比较自然受孕、非体外受精生育治疗与辅助生殖技术(ART)的产科并发症;调整亲代因素后ART仍与异常胎盘形成独立相关(aRR 6.19),新鲜胚胎移植亦相关(aRR 2.07)。
要点
- ART妊娠异常胎盘形成累积发生率8.7%,非ART妊娠为1.4%(P<.01)。
- 调整亲代因素后ART与异常胎盘形成独立相关,aRR 6.19(95%CI 1.84-20.82)。
- ART妊娠中新鲜胚胎移植与异常胎盘形成相关,aRR 2.07(95%CI 1.10-3.92)。
核心结论
- 调整潜在不孕因素后,辅助生殖技术仍与异常胎盘形成独立相关。
- 该风险应在患者咨询和临床管理中予以考虑,尤其当因非医学原因选择辅助生殖技术时。
- 新鲜胚胎移植对胎盘形成的影响需进一步研究。
研究设计与样本
- 美国单一生育中心前瞻性纳入2017年9月至2021年12月不孕后自然受孕、非体外受精生育治疗或辅助生殖技术妊娠者。
- 排除多胎妊娠与代孕妊娠,最终分析656例单胎活产:自然受孕92例、非体外受精生育治疗116例、辅助生殖技术448例。
- 从病历评估亲代特征、治疗参数与产科并发症,主要结局为医生判定的产科并发症。
主要发现
- 辅助生殖技术组异常胎盘形成39例,占8.7%(95%CI 6.3%-11.7%),非辅助生殖技术妊娠3例,占1.4%(95%CI 0.3%-4.1%)(P<.01)。
- 调整亲代因素后,辅助生殖技术与异常胎盘形成风险升高独立相关,aRR 6.19(95%CI 1.84-20.82,P<.01)。
- 辅助生殖技术妊娠中,新鲜胚胎移植与异常胎盘形成相关,aRR 2.07(95%CI 1.10-3.92,P=.025)。
- 新鲜胚胎移植妊娠的妊娠相关血浆蛋白A中位中倍数值为0.65(IQR 0.42-1.02 MoM),低于非辅助生殖技术妊娠的1.09 MoM(IQR 0.70-1.56 MoM)(P<.001)。
- 女性患者年龄中位数(IQR)分别为自然受孕37(35-39)岁、非体外受精生育治疗36(34-38)岁、辅助生殖技术38(35-41)岁(P<.01)。
临床怎么用
- 作者认为,辅助生殖技术相关的异常胎盘形成风险应在患者咨询和临床管理中予以考虑。
- 作者认为,尤其当因非医学原因选择辅助生殖技术时,应关注该风险。
- 作者提出,新鲜胚胎移植对胎盘形成的影响需进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obstetric complications linked to assisted reproductive technology could be confounded by underlying parental factors and were often derived from databases not designed to study these complications. With evolving assisted reproductive technology practices, it is unclear to what extent contemporary assisted reproductive technology independently contributes to obstetric risks. OBJECTIVE: We aimed to prospectively evaluate obstetric risks associated with contemporary fertility practices, adjusting for parental and assisted reproductive technology parameters. STUDY DESIGN: Prospective enrollment of patients with infertility who subsequently conceived unassisted, with non-in vitro fertilization fertility treatment, or assisted reproductive technology at a single US academic fertility center (September 2017-December 2021). Multiple gestations and surrogacy pregnancies were excluded from analysis. Parental characteristics, treatment parameters, and obstetric complications were assessed from medical records. The main outcome was physician-adjudicated obstetric complications (hypertensive disorders, abnormal placentation, fetal growth restriction, spontaneous preterm birth, and gestational diabetes). Maternal serum placental analyte level (pregnancy-associated plasma protein A) was also assessed by mode of conception. Cumulative incidences of obstetric complications by mode of conception were compared using chi-squared test. Univariable and multivariable log-binomial regression analyses were used to generate crude and adjusted risk ratios and their 95% confidence intervals to assess for associations between putative risk factors and abnormal placentation. Distributions of pregnancy-associated plasma protein A levels were compared using Kruskal-Wallis test, with correction for multiple pairwise comparisons with Dunn's test. All tests were 2-sided and conducted at the 0.05 level of significance. RESULTS: Of 2332 pregnancies approached for recruitment, 782 enrolled in the cohort, resulting in 656 singleton live births: 92 unassisted, 116 from non-in vitro fertilization fertility treatment, and 448 from assisted reproductive technology. The median (interquartile range) ages of the female patients were 37 (35-39), 36 (34-38), and 38 (35-41) years, respectively (P<.01). Abnormal placentation was the only assessed complication with a higher cumulative incidence in assisted reproductive technology vs nonassisted reproductive technology pregnancies (unassisted and non-in vitro fertilization fertility treatment combined). Thirty-nine patients had an abnormal placentation event in the assisted reproductive technology group, accounting for 8.7% (95% confidence interval, 6.3% to 11.7%) of assisted reproductive technology pregnancies, compared to 3, 1.4% (95% confidence interval, 0.3% to 4.1%), in non-assisted reproductive technology pregnancies (P<.01). Compared to non-assisted reproductive technology pregnancies, adjusting for parental factors, assisted reproductive technology was independently associated with a higher relative risk of abnormal placentation (adjusted relative risk, 6.19 [95% confidence interval, 1.84-20.82], P<.01). Within assisted reproductive technology pregnancies, fresh embryo transfer was the treatment parameter associated with abnormal placentation (adjusted relative risk, 2.07 [95% confidence interval, 1.10-3.92], P=.025). Pregnancy-associated plasma protein A level was particularly lower in fresh embryo transfer-conceived pregnancies (median multiple of the median value of 0.65 [interquartile range, 0.42-1.02 multiple of the median]), compared to non-assisted reproductive technology pregnancies (1.09 multiple of the median [interquartile range, 0.70-1.56 multiple of the median]) (P<.001). CONCLUSION: Adjusting for underlying infertility, assisted reproductive technology remained independently associated with abnormal placentation. This risk should be considered during patient counseling and clinical management, particularly when assisted reproductive technology is pursued for elective reasons. The impact of fresh embryo transfer on placentation warrants further investigation.
引用
- Huang D, Song Y, Qin J, et al. Reappraisal of adverse obstetric outcomes independently associated with contemporary fertility treatment practices: a US prospective cohort study. Am J Obstet Gynecol. 2025. PMID: 40754175. doi:10.1016/j.ajog.2025.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。